published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsPandit, 2021 0.95 [0.02; 50.33] Shashi Bhushan, 2021 4.39 [0.20; 98.33] 2.45[0.21; 28.37]Pandit, 2021, Shashi Bhushan, 202120%289moderatenot evaluable deathsdetailed resultsPandit, 2021 0.95 [0.02; 50.33] Shashi Bhushan, 2021 4.39 [0.20; 98.33] 2.45[0.21; 28.37]Pandit, 2021, Shashi Bhushan, 202120%289moderatenot evaluable clinical improvementdetailed resultsShashi Bhushan, 2021 0.68 [0.21; 2.20] 0.68[0.21; 2.20]Shashi Bhushan, 202110%242NAnot evaluable clinical improvement (14-day)detailed resultsPandit, 2021 8.77 [0.94; 81.67] Shashi Bhushan, 2021 0.68 [0.21; 2.20] 2.03[0.17; 24.32]Pandit, 2021, Shashi Bhushan, 2021275%281moderatenot evaluable clinical improvement (7-day)detailed resultsShashi Bhushan, 2021 1.91 [1.03; 3.53] 1.91[1.03; 3.53]Shashi Bhushan, 202110%222NAnot evaluable viral clearance detailed resultsPandit, 2021 2.33 [0.55; 9.83] Shashi Bhushan, 2021 2.77 [1.44; 5.32] 2.69[1.48; 4.87]Pandit, 2021, Shashi Bhushan, 202120%281moderatenot evaluable viral clearance by day 14detailed resultsPandit, 2021 10.23 [1.12; 93.35] Shashi Bhushan, 2021 0.00 [0.00; 0.01] 0.18[0.00; 435.69]Pandit, 2021, Shashi Bhushan, 2021298%1,359moderatenot evaluable viral clearance by day 7detailed resultsPandit, 2021 2.33 [0.55; 9.83] Shashi Bhushan, 2021 2.77 [1.44; 5.32] 2.69[1.48; 4.87]Pandit, 2021, Shashi Bhushan, 202120%281moderatenot evaluable serious adverse eventsdetailed resultsPandit, 2021 0.95 [0.02; 50.33] 0.95[0.02; 50.33]Pandit, 202110%39NAnot evaluable adverse eventsdetailed resultsPandit, 2021 1.68 [0.47; 5.97] 1.68[0.47; 5.97]Pandit, 202110%39NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:33 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290